Enbrel, a mainstay biologic in the inflammation category, fell 4% overall, with net selling price down 22%. Amgen attributed ...
Three days ago, on August 4, Amgen ( AMGN) released another strong earnings report. Its revenue was $10.1 billion, up 16.6% ...
Hackers recently accessed Amgen’s cloud environment, stealing sensitive patient health information and proprietary company ...
As Amgen’s flagship PCSK9 cholesterol drug Repatha enjoys a bit of a renaissance on the back of impressive cardiovascular ...
Amgen Q2 earnings preview: estimates, revenue outlook, Repatha/Tezspire growth, legacy declines & MariTide obesity pipeline ...
Amgen Inc. experienced a cyber incident that involved the theft of patient information and proprietary data stored in cloud ...
Amgen has ended development of its early-stage obesity drug AMG 513, foisting its hopes for a slice of the massive weight ...
Pharmaceutical company Amgen says it suffered a data breach after threat actors stole corporate data and patient information ...
Will this pharma company become a new leader in the weight loss market?
The recommendation is based on data from the Phase III VESALIUS-CV trial, which involved more than 12,000 patients.
Learn more about whether Amgen Inc. or Halozyme Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results